Company Pilot Therapeutics Holdings Inc. Other OTC

Pilot Therapeutics Holdings, Inc. is a holding company for Pilot Therapeutics, Inc. and is a specialty pharmaceutical company. Through lipid profiling and metabolism, the Company has developed a proprietary, lipid and genomic profiling research platform, termed Functional Liponomics. Using Functional Liponomics, the Company is developing novel, branded, therapeutic, pharmaceutical and over-the-counter (OTC) medical food products that are specifically designed to address dysfunctional lipid metabolism in chronic human diseases such as asthma, coronary heart disease, allergic rhinitis, cancer, cystic acne and rheumatoid arthritis. Pilot expects to launch its first product, Airozin, for adults and children regionally in April 2003 and nationally by 2004.